Semaglutide vs. Tirzepatide: How to Compare the Two Leading Weight Loss Injections

By Dr. Humberto Fernandez Miro, MD 

The question I field most often from patients who are ready to start treatment is some version of: which one should I pick, the Wegovy or the Zepbound? The short answer is that it depends on the patient, and anyone who gives you a single definitive answer without knowing your medical history, your insurance situation, and what has or hasn’t worked for you before is not giving you useful information. The longer answer is worth understanding in detail, because the differences between these two medications are real and clinically meaningful, and the choice between them is not arbitrary.

I have been prescribing both for several years in primary care, and the comparison has gotten more nuanced as the data has matured. What I can offer here is a framework for thinking through the decision rather than a verdict, because the verdict is different for different patients and that is exactly as it should be.

The Mechanism Difference That Drives Everything Else

Semaglutide and tirzepatide are not the same class of drug with different potency. They are related but mechanistically distinct, and the distinction matters for understanding why their clinical profiles differ.

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a gut hormone released after eating that signals satiety to the brain, slows gastric emptying, and regulates insulin release in a glucose-dependent manner. This is a well-characterized mechanism with a decade of clinical data behind it.

Tirzepatide is a dual agonist. It activates both the GLP-1 receptor and the GIP receptor, where GIP stands for glucose-dependent insulinotropic polypeptide, a second incretin hormone secreted in the proximal small intestine. GIP receptor activation in the central nervous system appears to amplify the satiety-signaling effect of GLP-1 receptor agonism in ways that produce greater appetite suppression than either receptor pathway alone. The combination also has metabolic effects on lipid handling and insulin sensitivity that appear to extend beyond what the GLP-1 mechanism produces by itself.

The practical result of this dual mechanism is higher average weight loss with tirzepatide compared to semaglutide at their respective approved doses. How much higher is a number that needs context to be meaningful.

The Efficacy Numbers, With Context

The landmark efficacy trial for semaglutide at the weight management dose is STEP 1, which showed average weight loss of approximately 14.9 percent of body weight at 68 weeks in patients with obesity but without type 2 diabetes. That is a population average. Some patients lost significantly more, some significantly less.

The landmark trial for tirzepatide is SURMOUNT-1, which showed average weight loss of 15.0 percent at the 5 mg dose, 19.5 percent at 10 mg, and 20.9 percent at 15 mg over 72 weeks in a similar population. At the highest dose, roughly a third of participants lost 25 percent or more of their body weight.

The comparison requires a note of caution: STEP 1 and SURMOUNT-1 are different trials with different populations and slightly different timeframes. A true head-to-head randomized trial at the weight management doses has not been completed. The best available direct comparison is SURPASS-2, which randomized patients with type 2 diabetes to tirzepatide at various doses versus semaglutide 1 mg, which is the diabetes dose rather than the weight management dose of 2.4 mg. Tirzepatide outperformed semaglutide at all three doses in that trial, but extrapolating across different doses and different populations requires care.

The honest clinical summary is that tirzepatide produces greater average weight loss than semaglutide, by somewhere in the range of 5 to 8 percentage points at equivalent therapeutic doses. That difference is statistically significant, clinically meaningful for many patients, and not large enough to make semaglutide a weak option. A medication that produces 15 percent average weight loss is still producing results that were only previously achievable with bariatric surgery.

Side Effect Profiles: More Similar Than Different

Both medications share a class-wide GI side effect profile dominated by nausea, constipation, and to a lesser degree vomiting and diarrhea. The mechanism is the same: delayed gastric emptying and central GLP-1 receptor activation in brainstem nausea centers. The severity is highest during dose escalation and attenuates significantly once a stable dose is maintained.

Discontinuation due to GI adverse effects runs at approximately 5 to 7 percent in the major trials for both drugs, which is not dramatically different from each other and is lower than discontinuation rates seen in real-world practice, where titration support is less intensive than in a clinical trial. The patients who stop these medications because of side effects are almost always stopping during the escalation phase, and the most common preventable cause is escalating too fast.

There is some clinical impression, supported partially by trial data, that tirzepatide produces slightly more nausea than semaglutide, particularly at the higher doses. The SURMOUNT-1 nausea rates were somewhat higher than what appeared in STEP 1 at comparable time points. This is not enough to make tirzepatide intolerable for most patients, but it is worth knowing as a baseline expectation, particularly for patients with a history of GI sensitivity.

Both weight loss injections carry the same class contraindications: a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and a history of pancreatitis warrants individual evaluation before starting either agent. These are absolute contraindications and do not depend on which specific medication is being considered.

Cardiovascular Data: Semaglutide Has More

The cardiovascular outcomes evidence base for semaglutide is larger and more mature than for tirzepatide, and this is a clinically relevant difference for certain patients.

The SELECT trial, published in 2023, enrolled over 17,000 patients with obesity and established cardiovascular disease but without type 2 diabetes, and found a 20 percent reduction in major adverse cardiovascular events with semaglutide 2.4 mg over a median follow-up of nearly four years. This is the first randomized controlled trial to demonstrate cardiovascular event reduction with a weight loss medication in a non-diabetic population. For patients with established heart disease, that data point matters.

Tirzepatide’s cardiovascular outcomes trial, SURMOUNT-CVOT, is ongoing and results are anticipated. The preclinical data and the cardiovascular secondary endpoints from the SURMOUNT program suggest a benefit is likely. The GIP receptor agonism may contribute to cardiometabolic protection beyond what GLP-1 agonism alone produces. But anticipated results are not available results. For a patient where cardiovascular risk reduction is the primary clinical priority alongside weight loss, semaglutide currently has the outcomes data and tirzepatide does not.

The Cost and Access Conversation

At full retail price before insurance, semaglutide 2.4 mg as Wegovy and tirzepatide 15 mg as Zepbound are priced within a similar range, typically between $1,200 and $1,400 per month at US pharmacies. For patients paying out of pocket, neither is accessible at that price point, and the conversation shifts to manufacturer savings programs, compounding pharmacy options, and lower-dose entry points.

Eli Lilly, which makes tirzepatide, offers LillyDirect pharmacy pricing that has consistently undercut retail pharmacy prices for patients without insurance coverage. Novo Nordisk has similar programs for semaglutide. The practical out-of-pocket cost through these channels, for patients who qualify, tends to run significantly below retail, though it still represents a meaningful monthly expense.

Commercial insurance coverage remains inconsistent and is moving in a difficult direction for many patients, with a number of employer plans having reduced or eliminated GLP-1 coverage in recent years. For Medicare patients, the GLP-1 Bridge program that launched in mid-2026 provides covered access to selected medications including both semaglutide and tirzepatide for eligible beneficiaries. The formulary status of each medication on any specific insurance plan is a practical factor that often determines the choice more than clinical considerations, and it is worth checking before the clinical conversation gets very far.

Which Patients Are Better Suited to Each

After years of prescribing both, the patient characteristics that tend to steer me toward one over the other have become clearer.

Tirzepatide makes more clinical sense for patients who have tried semaglutide and achieved a partial but insufficient response, for patients with significant insulin resistance and metabolic syndrome where the dual mechanism addresses multiple pathophysiological nodes simultaneously, and for patients where the maximum available weight loss is the priority and there is no insurance or access barrier that makes it impractical. The additional efficacy at the higher doses is real, and for patients who need it, it justifies the choice.

Semaglutide makes more clinical sense for patients with established cardiovascular disease where the SELECT outcomes data is directly relevant, for patients where semaglutide has existing insurance coverage and tirzepatide does not, and for patients who have specific concerns about tolerability and want to start with the agent that has the slightly lower nausea signal in the trial data. It also has a longer track record in clinical practice, which matters for patients who weigh familiarity.

In practice, the single most common driver of the choice is formulary coverage. The best medication is the one the patient can actually afford to take for years. A 20 percent average weight loss that is inaccessible at 3 months is not better than 15 percent that is consistently available. Both of these medications work. Getting the right one into the right patient’s hands at a price they can sustain is the clinical work that actually determines the outcome.

A Note on Switching Between Them

Patients sometimes ask whether they can switch from one to the other, either because of tolerability issues, insufficient response, or a change in insurance coverage. The answer is yes, switching is feasible and is done regularly in clinical practice.

Switching from semaglutide to tirzepatide because of an inadequate weight loss response is reasonable and supported by the mechanism: the additional GIP receptor pathway may produce a response in patients who plateaued on GLP-1 monotherapy. There is no required washout period between agents given their different receptor targets. Switching from tirzepatide to semaglutide, typically driven by insurance changes or cost, involves moving to a medication that may produce somewhat less appetite suppression, and patients should be counseled to expect a potentially different experience without interpreting the difference as a failure.

The clinical framing I use with patients is that both of these medications are treating the same underlying condition through related but not identical mechanisms. The choice between them is a starting point, not a permanent assignment. If the first choice is not working as well as needed, or if circumstances change, the other option remains available.

___

Dr. Humberto Fernandez Miro, MD, is a family medicine physician and clinical researcher with 25 years of practice in Miami, FL. He is a contributing medical writer at WeightLossPills.com.